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In his opinion piece, Wolfgang Weyers (2018) suggests that the practice of biopsying small lesions (<6 mm in diameter) without conspicuous clinical and/or dermoscopic features of melanoma is a key contributing factor to the so-called epidemic of melanoma overdiagnosis. He contends that these clinically non-diagnostic lesions often lack histopathologic criteria that allow precise classification, which leads to falsepositive diagnoses. He proposes delaying biopsy of lesions that are suspicious, but not diagnostic, for melanoma until features consistent with malignancy arise, the aim being to decrease diagnostic and biologic uncertainty and thereby minimize the potential for melanoma overdiagnosis together with its associated cost and morbidity. The view expressed by Dr. Weyers is intriguing, and the overarching concept raises important questions relevant to the diagnosis of melanoma.
1. What is the optimal sensitivity and specificity threshold for melanoma diagnosis? While taking a watch-and-wait approach until melanoma unequivocally declares itself will increase specificity and possibly decrease the likelihood of overdiagnosis, this approach implies a concomitant decrease in sensitivity for melanoma detection. This, in turn, may result in some individuals developing advanced stage melanomas due to the missed opportunity of early detection. This is not an uncommon scenario occurring in patients with difficult to detect melanoma subtypes, such as nodular, desmoplastic, nevoid, amelanotic, or spitzoid melanoma. Further research is needed to determine if the benefits of a reduction in overdiagnosis and unnecessary biopsies outweigh the harm that may result from missed early melanoma detection. is not our experience that pathologists issue a diagnosis of melanoma as a default option when the diagnosis is difficult; instead, they usually admit diagnostic uncertainty.
While the biopsy of small lesions and small partial biopsies of lesions have undoubtedly contributed to an inflation of descriptive pathology reports (e.g., "atypical melanocytic proliferation"), such evasive diagnoses should not enter melanoma statistics and therefore cannot be responsible for the increase in the reported incidence of melanoma.
We agree with Dr. Weyers that wholesale biopsy (especially partial biopsies) of small, non-palpable, equivocal lesions should be discouraged. We also agree that if a lesion has compelling clinical or dermoscopic features for melanoma, then a biopsy should be performed, irrespective of the lesion's diameter. However, while there are benefits to the watch-and-wait approach for small equivocal lesions as outlined by Dr. Weyers, there are also potential pitfalls and unanswered questions that require further study. We posit that a combined approach using morphologic (clinical examination, dermoscopy, confocal microscopy, etc.), comparative (e.g., ugly duckling sign), temporal (monitoring using TBP, dermoscopy, confocal microscopy), and genomic data (e.g., non-invasive molecular assays obtained via microbiopsies, tape-stripping, etc.), augmented someday by machine learning approaches, will likely address some of the core issues described in the opinion piece by Dr. Weyers. Furthermore, as our understanding of the biology of melanocytic neoplasms continues to expand, the prevalence of lesions with diagnostic and biologic uncertainty will decrease, but complete knowledge of the potential nature of every lesion over the course of each individual's life will, of course, remain elusive.
(TBP) and digital dermoscopic monitoring is one standard of care used in many clinics that screen patients at high risk for melanoma. 
